Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

HK:0013 Stock Latest News

The FlyHutchmed announces filings for Orpathys accepted for review in Japan, Europe3h agoHCM
HUTCHMED Combination Therapy Delivers Strong Phase III Lung Cancer ResultsCompany AnnouncementsHUTCHMED Combination Therapy Delivers Strong Phase III Lung Cancer Results6d ago
Company AnnouncementsHUTCHMED’s ORPATHYS Combo Delivers Phase III Survival Gains in MET-Driven Lung Cancer1w ago
Company AnnouncementsHUTCHMED Seals Global HMPL-A830 Licensing Deal With GSK Outside China1w ago
HUTCHMED to showcase pivotal lung cancer and broad oncology data at ESMO 2026Company AnnouncementsHUTCHMED to showcase pivotal lung cancer and broad oncology data at ESMO 20261M ago
The FlyHutchmed price target raised to $18 from $16 at BofA1M agoHCM
The FlyHutchmed upgraded to Buy from Hold at HSBC1M agoHCM
HUTCHMED Licenses First-in-Class KRAS-EGFR Cancer Therapy to GSK in US$1.3 Billion DealCompany AnnouncementsHUTCHMED Licenses First-in-Class KRAS-EGFR Cancer Therapy to GSK in US$1.3 Billion Deal1M ago
Company AnnouncementsHUTCHMED’s ORPATHYS–TAGRISSO Combo Delivers First-Line PFS Gain in MET-Driven Lung Cancer2M ago
Company AnnouncementsHUTCHMED’s ORPATHYS Combo Delivers First-Line Benefit in MET-Driven Lung Cancer2M ago